Isarna Therapeutics Announces Phase 2 Clinical Data Presentations at Upcoming Ophthalmology Conferences

MUNICH--(BUSINESS WIRE)--Isarna Therapeutics today announced upcoming oral presentations at the OIS Retina Innovation Summit on May 4th and the Association for Research in Vision and Ophthalmology (ARVO) Meeting on May 7th, both in Seattle, WA. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, will present updated clinical data from its Phase 2 BETTER study evaluating the company’s lead program, ISTH0036. ISTH0036 is an RNA-based antisense molecule that blocks the production of transforming